TC 14012

Discontinued Product

4300 has been discontinued.

View all Chemokine CXC Receptors products.
说明: CXCR4 antagonist; ACKR3 (CXCR7) agonist
纯度: ≥95% (HPLC)
说明书
引用文献
评论
文献 (1)

生物活性 for TC 14012

TC 14012 is a CXCR4 antagonist and ACKR3 (CXCR7) agonist (EC50 = 350 nM for CXCR7).

技术数据 for TC 14012

分子量 2066.43
公式 C90H140N34O19S2
序列 RRACYXKXPYRXCR

(Modifications: Disulfide bridge: 4-13, Ala-3 = 3-(2-naphthalenyllalanine), X-6 and X-12 = L-Citrulline, X-8 = D-Citrulline, Arg-14 = C-terminal amide)

储存 Store at -20°C
纯度 ≥95% (HPLC)
CAS Number 368874-34-4
PubChem ID 90488928
InChI Key SGDDHDBBOJNZKY-UXNLHULBSA-N
Smiles [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for TC 14012

分析证书/产品说明书
选择另一批次:

按产品操作查看相关产品

查看全部 Chemokine CXC Receptor Antagonists

关键词: TC 14012, TC 14012 supplier, TC14012, cxcr4, antagonists, inverse, agonists, cxcr7, chemokines, Chemokine, CXC, Receptors, 4300, Tocris Bioscience

篇 TC 14012 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 TC 14012 的引用文献。

TC 14012 的评论

目前没有该产品的评论。 Be the first to review TC 14012 and earn rewards!

Have you used TC 14012?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.